From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin
Fecal Occult Blood (FOB)
UP446
250 mgs
500 mgs
Celecoxib
200 mgs
Placebo
Visit
Baseline
Positive
0
30 Days
2
1
90 Days
3
5
4
Total per study period
7